Back
Corcept Therapeutics, Inc. 10K Form
Sell
28
CORT
Corcept Therapeutics, Inc.
Last Price:
$33.89
Seasonality Move:
8.92%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-01 | 10Q | CORT/Corcept Therapeutics, Inc. Quarterly |
| 2023-11-01 | 10Q | CORT/Corcept Therapeutics, Inc. Quarterly |
| 2023-08-02 | 10Q | CORT/Corcept Therapeutics, Inc. Quarterly |
| 2023-05-03 | 10Q | CORT/Corcept Therapeutics, Inc. Quarterly |
| 2022-11-03 | 10Q | CORT/Corcept Therapeutics, Inc. Quarterly |
| 2022-08-04 | 10Q | CORT/Corcept Therapeutics, Inc. Quarterly |
Receive CORT News And Ratings
See the #1 stock for the next 7 days that we like better than CORT
CORT Financial Statistics
Sales & Book Value
| Annual Sales: | $761.4M |
|---|---|
| Cash Flow: | $38.4M |
| Price / Cash Flow: | 28.79 |
| Annual Sales: | $6.11 |
| Price / Book: | 5.59 |
Profitability
| EPS (TTM): | 0.81810 |
|---|---|
| Net Income (TTM): | $98.2M |
| Gross Margin: | $748.4M |
| Return on Equity: | 14.97% |
| Return on Assets: | 11.83% |
Corcept Therapeutics, Inc. Earnings Forecast
Key Corcept Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 21 years for CORT is 98.30%.
-
The Selling, General & Administrative Expenses for CORT have been equal to 58.93% of Gross Profit Margin.
-
The Research & Development expenses have been 33.48% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of CORT is 12.89% of Total Revenues.
-
Per Share Earnings over the last 25 years have been positive in 13 years.
Corcept Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | CORT |
| CUSIP: | 218352 |
| Website: | corcept.com |
Debt
| Debt-to-Equity Ratio: | 0.01 |
|---|---|
| Current Ratio: | 2.89 |
| Quick Ratio: | 2.6 |
Price-to-Earnings
| Trailing P/E Ratio: | 41.6 |
|---|---|
| Forward P/E Ratio: | 21.17 |
CORT Technical Analysis vs Fundamental Analysis
Sell
28
Corcept Therapeutics, Inc. (CORT)
is a Sell
Is Corcept Therapeutics, Inc. a Buy or a Sell?
-
Corcept Therapeutics, Inc. stock is rated a SellThe current Corcept Therapeutics, Inc. [CORT] share price is $34.04. The Score for CORT is 28, which is 44% below its historic median score of 50, and infers higher risk than normal.